Sacubitril/Valsartan for CKD5 Stage Dialysis Patients

Summary

Hemodialysis or peritoneal dialysis CKD5 patients were randomly divided into Sacubitril/Valsartan and irbesartan treatment groups. Comparing the blood pressure, survival rates, the cardiac function, renal function,and adverse reactions of two groups, to evaluate whether the efficacy and safety of Sacubitril/Valsartan in the treatment of patients with CKD dialysis combined with heart failure is superior to that of irbesartan.

Timeline

Start

2020-08-01

Primary completion

2023-03-01

Completion

2023-03-08

Drugs

Indications